Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 3—March 2007

Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone

Christopher J. Graber*Comments to Author , Margaret K. Wong*, Heather A. Carleton*, Françoise Perdreau-Remington*, Barbara L. Haller*, and Henry F. Chambers*
Author affiliations: *San Francisco General Hospital, University of California, San Francisco, California, USA;

Main Article


Antimicrobial susceptibility profiles of blood isolate from November 2005, blood isolate from February 2006, and lumbar isolate from April 2006*

Antimicrobial drugMIC (μg/mL) and CLSI interpretation
Nafcillin>2 R16 R>2 R
Clindamycin2 I≤0.25 S<0.25 S
Erythromycin4 I>8 R>4 R
Trimethoprim-sulfamethoxazole<0.5/9.5 S≤0.25/5 S<0.5/9.5 S
Tetracycline<1 S≤0.5 S†<1 S
Rifampin<1 S≤0.25 S<1 S
Ciprofloxacin>2 R>4 R>2 R
Levofloxacin>4 RND>4 R
Gentamicin<1 S≤0.5 S2 S
Vancomycin<2 S2 S8 I
4–6 I‡
DaptomycinND1 S
LinezolidND2 S2 S
TigecyclineND0.125 S0.125 S

*CLSI, Clinical and Laboratory Standards Institute; R, resistant; I, intermediately resistant; S, susceptible; ND, not done.
†Susceptibility to doxycycline performed instead of to tetracycline.
‡Confirmatory susceptibility by E-test and growth on vancomycin (6 µg/mL) agar screen plates.
§Interpreted as nonsusceptible by the Centers for Disease Control and Prevention. Formal CLSI breakpoints for daptomycin resistance have not been established.

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.